SCHEMBL2836644

SCHEMBL2836644

COc1cc(C)c(S(=O)(=O)N2CCCCC2COc2ccnc(N3CCCC3Cc3ccccn3)n2)c(C)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASP3 P42574 8/20 0.38
CASP7 P55210 6/20 0.37
RAB9A P51151 1/20 0.36
GNRHR P30968 2/20 0.36
ATM Q13315 1/20 0.36
ALDH1A1 P00352 2/20 0.35
LMNA P02545 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
MCOLN3 Q8TDD5 1/20 0.35
KDM4E B2RXH2 1/20 0.35
MAPT P10636 1/20 0.35
HSD17B10 Q99714 1/20 0.35
PDE5A O76074 1/20 0.35
CASP1 P29466 1/20 0.34
CASP2 P42575 1/20 0.34
CASP4 P49662 1/20 0.34
CASP9 P55211 1/20 0.34
CASP6 P55212 1/20 0.34
CASP8 Q14790 1/20 0.34
ADORA2A P29274 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2840106 0.98 CASP3 (0.39) CASP3CASP7RAB9AGNRHRCASP1
SCHEMBL2836273 0.98 CASP3 (0.39) CASP3CASP7RAB9AGNRHRCASP1
SCHEMBL2834851 0.90 CASP3 (0.38) CASP3CASP7CASP1CASP6ADORA2A
SCHEMBL2835368 0.87 GNRHR (0.37) CASP3CASP7RAB9AGNRHRATM
SCHEMBL2836786 0.85 KMT2A (0.39) CASP3CASP7RAB9AALDH1A1LMNA
SCHEMBL2832787 0.85 GNRHR (0.38) CASP3CASP7RAB9AGNRHRALDH1A1
SCHEMBL2832996 0.84 KMT2A (0.40) CASP3CASP7RAB9AALDH1A1LMNA
SCHEMBL2835907 0.84 ALDH1A1 (0.38) CASP3CASP7ALDH1A1LMNASMN1; SMN2
SCHEMBL2835615 0.83 ALDH1A1 (0.40) CASP3CASP7RAB9AALDH1A1KDM4E
SCHEMBL2835507 0.82 BDKRB1 (0.40) GNRHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2356101-B1 PYRIMIDINE- AND TRIAZINE-SULFONAMIDE DERIVATIVES AS BRADYKININ B1 RECEPTOR (B1R) INHIBITORS FOR THE TREATMENT OF PAIN GRUENENTHAL GMBH (DE) 2013-02-27 EP claimed
US-8269000-B2 Substituted pyrimidine and triazine compounds GRUENENTHAL GMBH (DE) 2012-09-18 US claimed
US-20100173889-A1 Substituted Pyrimidine and Triazine Compounds GRUENENTHAL GMBH (DE) 2010-07-08 US claimed
US-8269000-B2 Substituted pyrimidine and triazine compounds GRUENENTHAL GMBH (DE) 2012-09-18 US disclosed
US-20100173889-A1 Substituted Pyrimidine and Triazine Compounds GRUENENTHAL GMBH (DE) 2010-07-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100173889-A1 Substituted Pyrimidine and Triazine Compounds ADORA2B, CCNB1, TYMS CASP3 1252/4885CASP7 1641/4885RAB9A 134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.